Today's vaccine debate will be outdated if Inovio succeeds in developing DNA vaccines. Imagine a single needle shot that can cure Ebola.
Major pharmaceuticals companies have formed a partnership with Genomics England in the first step towards using genetic data from NHS patients.
“Mad Money” host Jim Cramer on why this rally won’t last forever and why you should take some off the table on this.
A Biogen Alzheimer's drug showed a significant slowing of the disease's hallmark cognitive declines.
Over the past five years, investor money is increasingly moving toward consumer software and later-stage life science ventures, a trend that could help develop new treatments.
Data from eVestment show which stocks are poised to make a big run in 2015, based on the names institutional investors have already been trading.
Regeneron Pharmaceuticals' top-selling eye drug, Eylea, bested Roche's Lucentis and Avastin in a U.S.-sponsored study in diabetes-related vision loss.
European markets ended mixed on Wednesday after seesawing for much of the session, with indexes pressures by a staggering slump in Greek bank stocks.
Here are the fund managers Morningstar considers the best of the best.
The Swiss franc soared—and Swiss stocks tanked—as that country's central bank shocked markets Thursday with a move to scrap a cap against the euro.
Stocks dropped Monday after a second weekly loss.
Foundation Medicine CEO Michael Pellini tells CNBC, "It's an important day for patients battling cancer."
CNBC's Meg Tirrell, and Michael Pellini, Foundation Medicine president & CEO, discuss the benefits of Roche's majority stake in Foundation Medicine.
Healthcare M&A looks set to be strong again this year, following deals from Shire and Roche. But Goldman Sachs says energy's a sector to watch too.
Swiss drug maker Roche plans to acquire a majority stake in Foundation Medicine by buying a combination of outstanding and newly issued shares.
The JPMorgan health care conference hadn't even officially begun when the first big piece of news of the week hit: Irish drugmaker Shire said Sunday morning it's purchasing orphan-drug company NPS Pharmaceuticals for $5.2 billion.
European shares closed mixed on Monday, with Greece struck by renewed political uncertainty after its politicians failed to agree on a new president.
European shares closed mixed on Friday, with Italian banking stocks and the health care sector weighing on wider benchmarks.
The health-care sector tends to outperform the overall market during flu season. Who else stands to gain?
There are few new cancer drugs to treat kids, and not much research is being done.